• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
183508 165 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  $ }+ _( Y- r% V2 y
1 \/ ]# ~& y, ^7 @' J+ j, M
' b, G4 b$ |5 g+ g% a8 {
Sub-category:0 I+ d5 N1 `  {4 x8 U2 r
Molecular Targets # U9 {8 q& P) {7 v; T

3 ?/ E. X. q. O$ `2 C7 y) X" s+ x. T. x2 P! A& U- q6 Z+ X$ p
Category:8 Q9 K! a' \8 u* v
Tumor Biology 9 S% w3 ~4 a  \6 X7 N) M( R' L; T3 d! `

% B: m# L. T. B  |
5 N. j  b) E, N5 DMeeting:
5 K, b. I* _" u: r  {, L2011 ASCO Annual Meeting
+ j: v  q! q; ]* R1 o: ]
4 w% _+ I9 h8 w3 i9 z; R6 d( }- ^+ w& I3 `, p7 {( r# {4 h
Session Type and Session Title:
( y" a# d3 ~8 \( h! w4 xPoster Discussion Session, Tumor Biology , }! L4 M9 `  [5 Z( V  \

6 g( t: x6 [% [; u# K& S# y# {5 {' B9 M) _$ D
Abstract No:& Y6 k. E+ Z2 d  z6 u4 L
10517
6 N: K% q7 p* c+ _& ?2 B2 Y2 n1 |# J4 X* n& ^, d7 {1 i7 w

2 m! `: i+ R, ~, W" dCitation:4 R7 ?- b" B* u9 f7 q
J Clin Oncol 29: 2011 (suppl; abstr 10517)
7 R* E1 p; ?$ G/ @) Z: N3 u- C9 v# m3 ]; Y
1 A; C3 z( s4 f8 z1 c3 U
Author(s):
' h; d. S" T: g& L' GJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
) l. s+ i7 T3 q! ]4 i. @7 X
: o4 A) Q/ R' `$ s+ g* D% D% q' J9 h6 J1 @. W& Q8 N

2 y- J( P% _6 oAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
" F& M' N6 X  d$ q/ e  W: U& `9 B7 M9 ]+ m3 C% p
Abstract Disclosures
$ p( E* @' k3 X6 ~6 ^% J
- v& X, \9 E. w: f( G) IAbstract:
4 S' }8 H, w/ h) Z. j0 s; k6 p4 u) D$ L% P
+ ]  C; n9 a6 R) v( Q: l8 [; v% H
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
0 |4 q5 w1 M& {4 L2 H
- X- F5 H: G$ Z8 x: q2 E6 c# M
% k" w* b9 `9 `" x+ m4 _) y) u5 x
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ) D0 z4 b: R' V
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
1 |2 p; H1 A8 Z  \" X2 U0 a3 d
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
5 K3 S! n" I8 z" v; j易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。. q6 N- i) B( [3 f
ALK一个指标医院要900多 ...
! j8 Q& U# u) G
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?3 K$ G7 ~$ t, s, q* I6 l; H! I
" S1 K& g6 A% y. G! E) G, O
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表